Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Japan

Eisai Targets Cancer

July 2007 | Company News Alert

One of Japan's largest drugmakers, Eisai, is to make oncology a strategic priority in the mid-term ahead of US patent expiry of its best-selling product, the Alzheimer's disease therapeutic Aricept (donepezil), in 2010. BMI endorses this approach but fears that the company has left it too late, considering how long it takes for an investigational drug to move through clinical trials. Moreover, Eisai is not the first drugmaker with this plan. For example, Swiss pharmaceutical player Roche has been firmly concentrating on discovering cancer drugs for nearly 10

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
Merck Launches Isentress

Companies / Japan Merck & Co has launched its integrase inhibitor for HIV Isentress (raltegravir) in Japan through its local subsidiary Banyu.
July 2008
Regulatory Climate Improves

Companies / Japan BMI has reinforced its favourable assessment of Japan's regulatory environment after the country's Pharmaceuticals and Medical Devices Agency (PMDA) delineated a biosimilar approval pathway and promised...
March 2007
Novartis Files Xolair In Japan

Companies / Japan Swiss drug major Novartis has filed its Xolair asthma treatment in Japan. If approved, the monoclonal antibody will be Japan's first-in-class therapy for severe forms of the respiratory disorder. Xolair...
July 2006
Pfizer, Astellas Launch Rival Bladder Drugs

Companies / Japan US drug major Pfizer and Japanese major Astellas are launching rival therapies for hyperactive bladder in Japan. The US firm's Detrusitol will be priced at JPY204.3 (US$1.78) per 4mg capsule under the...
June 2006
Japan's Leading Generics Makers To Join Forces

Companies / Japan However, a recent survey conducted by Japanese generics manufacturer Sawai claims 90.6% of Japanese consumers are willing to use generics, but only 2.6% have tried to get them prescribed due to apprehension...
March 2006


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2008 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS